Molecular Determinants for the Tissue Specificity of SERMs
暂无分享,去创建一个
[1] Y. Yamasaki,et al. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. , 1994, The Journal of biological chemistry.
[2] F. Miralles,et al. Characterization of the proximal estrogen-responsive element of human cathepsin D gene. , 1994, Molecular endocrinology.
[3] J. Williams,et al. Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer. , 1999, Experimental and molecular pathology.
[4] Myles Brown,et al. Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.
[5] H. Moch,et al. Tissue microarrays for gene amplification surveys in many different tumor types. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] V. Giguère,et al. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. , 1999, Molecular cell.
[7] S. Gapstur,et al. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. , 2001, Journal of the National Cancer Institute.
[8] C. Glass,et al. The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.
[9] G. Martin,et al. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. , 1994, Science.
[10] M. Tzukerman,et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. , 1994, Molecular endocrinology.
[11] P. Chambon,et al. Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen. , 1990, The EMBO journal.
[12] K. Horwitz,et al. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. , 1997, Molecular endocrinology.
[13] P. Chambon,et al. Promoter specificity of the two transcriptional activation functions of the human oestrogen receptor in yeast. , 1992, Nucleic acids research.
[14] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[15] S. Inoue,et al. Molecular cloning and characterization of mouse EBAG9, homolog of a human cancer associated surface antigen: expression and regulation by estrogen. , 2001, Biochemical and biophysical research communications.
[16] R. Evans,et al. HATs on and beyond chromatin. , 2001, Current opinion in cell biology.
[17] T. Rohan,et al. Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.
[18] L. Freedman,et al. Nuclear receptor cofactors as chromatin remodelers. , 1999, Current opinion in genetics & development.
[19] R. Shiu,et al. Mechanism of estrogen activation of c-myc oncogene expression. , 1992, Oncogene.
[20] David A. Agard,et al. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.
[21] S. Inoue,et al. Isolation of Estrogen-Responsive Genes with a CpG Island Library , 1998, Molecular and Cellular Biology.
[22] L. Soucek,et al. Making decisions through Myc , 2001, FEBS letters.
[23] T. Tuschl,et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.
[24] B. Katzenellenbogen,et al. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. , 1998, Molecular endocrinology.
[25] M. Lazar,et al. Transcriptional Repression by Nuclear Hormone Receptors , 2000, Trends in Endocrinology & Metabolism.
[26] Zbigniew Dauter,et al. Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.